Liposomal‐Naringenin Radiosensitizes Triple‐Negative Breast Cancer MDA‐MB‐231 Cells In Vitro

Abstract

Background. Naringenin has shown great promise in the realm of cancer therapeutics, demonstrating excellent cytotoxic action toward cancer cells and the enhanced effects of radiation therapy in vitro. However, the medicinal value of naringenin is severely limited clinically by poor bioavailability. Thus, multiple drug‐delivery strategies for overcoming this limitation have been developed, of which liposomes are considered the most suitable due to their amphiphilic, modifiable, and biocompatible characteristics. In this study, we investigated the role of naringenin and liposomal‐delivered naringenin as adjuncts to radiotherapy in the MDA‐MB‐231 triple‐negative breast cancer cell line in vitro. Materials and Methods. Liposomal‐naringenin was synthesized by thin‐film hydration and extrusion and was characterized by spectrophotometry, dynamic light scattering, and zeta potential. The effects of free‐from naringenin and liposomal‐naringenin were evaluated toward MDA‐MB‐231 cell viability when combined with varying doses of radiation. Additionally, cell growth patterns, morphology, and colony formation were evaluated. Results. The analysis demonstrated IC50 values of 387.5 and 546.6 µg/ml for naringenin and liposomal‐naringenin, respectively. Naringenin and liposomal‐naringenin significantly lowered cell viability, proliferation, and colony formation dose‐dependently, as compared to radiation in isolation. Conclusion. The findings presented herein concur with previous accounts of the radiosensitizing potential of naringenin and further highlight the considerable biomedical application of liposomal‐naringenin within the realm of radiotherapy.